After a couple of successful intellectual property and marketing fights with competitors, MAKO Surgical Corp. is getting back to business by hiring a new senior vice president of marketing.
Dawson Takes Over MAKO Marketing
1 min read Premium comments
On June 3, 2013, the company announced the appointment of Ian Dawson to the position. Dawson is assuming responsibility for the company’s commercial marketing activities formerly overseen by Ivan Delevic. Delevic is transitioning to the position of senior vice president of corporate development. Both men will report to the company’s President and CEO Maurice Ferré, M.D.
According to the company announcement, Dawson has over 25 years of experience in marketing, with the majority of the experience in the medical device field. From June 2008 through May 2013, he served as vice president of North America marketing for Smith & Nephew Advanced Wound Management, a manufacturer and supplier of advanced wound dressings and devices. He was responsible for managing the entire marketing function for North America.
From May 2004 to June 2008, Dawson held various marketing leadership positions with Zimmer, Inc., including senior director of U.S. knee marketing, where he was responsible for directing all marketing programs and activities related to Zimmer’s knee products. From July 2001 to April 2004, he served as the vice president – Product Group Knee, for Centerpulse Orthopedics Ltd., a manufacturer and supplier of orthopedic implants. Dawson holds a B.S. in Applied Biology from Chelsea College, University of London and a Diploma in Management Studies from Exeter College of Plymouth Polytechnic.
MAKO Surgical Corp. markets its RIO Robotic-Arm Interactive Orthopedic system, joint specific applications for the knee and hip, and proprietary RESTORIS implants for orthopedic procedures called MAKOplasty. The RIO is a surgeon-interactive tactile surgical platform that incorporates a robotic arm and patient-specific visualization technology, which enables “precise, consistently reproducible bone resection for the accurate insertion and alignment of MAKO’s RESTORIS implants.” The MAKOplasty solution incorporates technologies enabled by an intellectual property portfolio including more than 300 U.S. and foreign, owned and licensed, patents and patent applications.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.